SG11201501510SA - Combinations of sglt2 inhibitors and antihypertensive drugs - Google Patents

Combinations of sglt2 inhibitors and antihypertensive drugs

Info

Publication number
SG11201501510SA
SG11201501510SA SG11201501510SA SG11201501510SA SG11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA
Authority
SG
Singapore
Prior art keywords
combinations
antihypertensive drugs
sglt2 inhibitors
sglt2
inhibitors
Prior art date
Application number
SG11201501510SA
Inventor
Naoki Kojima
J Richard Roman
Noriyuki Miyata
Teisuke Takahashi
Hideki Tomoike
Takuya Takeda
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of SG11201501510SA publication Critical patent/SG11201501510SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201501510SA 2012-08-30 2013-08-30 Combinations of sglt2 inhibitors and antihypertensive drugs SG11201501510SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695016P 2012-08-30 2012-08-30
PCT/JP2013/073300 WO2014034842A1 (en) 2012-08-30 2013-08-30 Combination of sglt2 inhibitor and anti-hypertension drug

Publications (1)

Publication Number Publication Date
SG11201501510SA true SG11201501510SA (en) 2015-04-29

Family

ID=50183647

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501510SA SG11201501510SA (en) 2012-08-30 2013-08-30 Combinations of sglt2 inhibitors and antihypertensive drugs

Country Status (17)

Country Link
US (1) US9320727B2 (en)
EP (1) EP2891499A4 (en)
JP (2) JP6198013B2 (en)
KR (1) KR20150046125A (en)
CN (1) CN104780942A (en)
AU (1) AU2013309904A1 (en)
BR (1) BR112015004012A2 (en)
CA (1) CA2883118A1 (en)
HK (1) HK1208621A1 (en)
IN (1) IN2015DN01975A (en)
MX (1) MX2015002572A (en)
PH (1) PH12015500434A1 (en)
RU (1) RU2015110979A (en)
SG (1) SG11201501510SA (en)
TW (1) TW201414472A (en)
WO (1) WO2014034842A1 (en)
ZA (1) ZA201502009B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (en) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 A pharmaceutical composition comprising SGLT-2 inhibitor and angiotensin receptor blocker
CN109806397A (en) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 SGLT2 inhibitor combines the purposes in the drug of the diseases such as preparation treatment hypertension with ARB
KR102131359B1 (en) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 A pharmaceutical composition with an improved stability
JPWO2021049612A1 (en) * 2019-09-13 2021-03-18
WO2022176981A1 (en) * 2021-02-19 2022-08-25 大正製薬株式会社 Oral film preparation
KR20230061281A (en) * 2021-10-27 2023-05-08 지용하 Composition comprising angiotensin receptor blocker and SGLT2 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
DE102004048388A1 (en) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5194588B2 (en) 2006-07-06 2013-05-08 大正製薬株式会社 Diabetes preventive or therapeutic agent containing 1-thio-D-glucitol derivative as an active ingredient
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
WO2010048358A2 (en) * 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
RS53761B1 (en) * 2009-04-16 2015-06-30 Taisho Pharmaceutical Co. Ltd. Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue.
JP2012528170A (en) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー Method for treating type 2 diabetic patients resistant to prior treatment with another anti-diabetic drug using SGLT2 inhibitors and compositions thereof

Also Published As

Publication number Publication date
HK1208621A1 (en) 2016-03-11
US9320727B2 (en) 2016-04-26
US20150320721A1 (en) 2015-11-12
BR112015004012A2 (en) 2017-07-04
JPWO2014034842A1 (en) 2016-08-08
TW201414472A (en) 2014-04-16
KR20150046125A (en) 2015-04-29
RU2015110979A (en) 2016-10-20
JP2017186353A (en) 2017-10-12
EP2891499A1 (en) 2015-07-08
PH12015500434B1 (en) 2015-04-20
IN2015DN01975A (en) 2015-08-14
CN104780942A (en) 2015-07-15
PH12015500434A1 (en) 2015-04-20
JP6198013B2 (en) 2017-09-20
CA2883118A1 (en) 2014-03-06
WO2014034842A1 (en) 2014-03-06
ZA201502009B (en) 2016-07-27
AU2013309904A1 (en) 2015-03-19
EP2891499A4 (en) 2016-02-24
JP6358515B2 (en) 2018-07-18
MX2015002572A (en) 2015-06-05

Similar Documents

Publication Publication Date Title
HRP20180953T1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
IL237849B (en) Ret inhibitors and uses of same
HK1207372A1 (en) Benzo [c]isoxazoloazepine bromodomain inhibitors and uses thereof [c]
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
IL225862A0 (en) Nampt and rock inhibitors
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1199705A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
IL233681B (en) Pharmaceutical compositions and methods
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
ZA201502009B (en) Combinations of sglt2 inhibitors and antihypertensive drugs
EP2852397A4 (en) Huwentoxin-iv variants and methods of use
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2688901A4 (en) INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
GB201208315D0 (en) Pharmaceutical methods and compositions
GB201203987D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203988D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203621D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203617D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203614D0 (en) Selective glycosidase inhibitors and uses thereof